There are 2789 resources available
478P - TA-ness classification discriminates RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) who may benefit from antiEGFR treatment
Presenter: Cristina Santos
Session: ePoster Display
534P - Larotrectinib in non-CNS TRK fusion cancer patients: Outcomes by prior therapy and performance status
Presenter: Alexander Drilon
Session: ePoster Display
535P - Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase (TRK) fusion cancer
Presenter: Marcia S. Brose
Session: ePoster Display
363P - Clinical significance of telomerase reverse transcriptase (TERT) promoter mutations, telomere length and MGMT promoter methylation status in newly diagnosed and recurrent IDHwildtype glioblastoma (GBM) patients (PTS): A large mono-institutional study
Presenter: Giuseppe Lombardi
Session: ePoster Display
364P - Implementation of a comprehensive streamlined next generation sequencing (NGS) test for glioma including detection of the 1p/19q codeletion
Presenter: Sian Wood
Session: ePoster Display
1470P - Oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence
Presenter: Thatcher Heumann
Session: ePoster Display
1471P - Overall survival by BRCA and ATM mutation status in patients with metastatic pancreatic cancer: Findings from the PRIOR-2 study
Presenter: Gboyega Adeboyeje
Session: ePoster Display
1472P - Circulating tumor DNA in unresectable pancreatic cancer is a strong predictor of response to first-line therapy: The KRASCIPANC study
Presenter: Camille Evrard
Session: ePoster Display
1473P - Gender differences in treatment allocation and survival in a real-world metastatic pancreatic cancer cohort
Presenter: Esther Pijnappel
Session: ePoster Display
1474P - Patient characteristics and treatment patterns in patients with metastatic pancreatic cancer by BRCA/ATM status in the PRIOR-2 study
Presenter: Maria Sierra
Session: ePoster Display